Application of mesenchymal stem cells in paediatrics

Open access


Mesenchymal stem cells (MSC) were described by Friedenstein in the 1970s as being a group of bone marrow non-hematopoietic cells that are the source of fibroblasts. Since then, knowledge about the therapeutic potential of MSCs has significantly increased. MSCs are currently used for the treatment of many diseases, both in adults and children. MSCs are used successfully in the case of autoimmune diseases, including rheumatic diseases, diabetes mellitus type 1, gastroenterological and neurological diseases. Moreover, treatment of such organ disorders as damage or hypoxia through application of MSC therapy has shown to be satisfactory. In addition, there are some types of congenital disorders, including osteogenesis imperfecta and Spinal Muscular Atrophy, that may be treated with cellular therapy. Most studies showed no other adverse effects than fever. Our study is an analysis that particularly focuses on the registered trials and results of MSCs application to under 18 patients with acute, chronic, recurrent, resistance and corticosteroids types of Graft-versus-Host Disease (GvHD). Stem cells currently play an important role in the treatment of many diseases. Long-term studies conducted on animals have shown that cell therapy is both effective and safe. The number of indications for use of these cells in the course of treatment of people is constantly increasing. The results of subsequent studies provide important data justifying the application of MSCs in the course of treatment of many diseases whose treatment is ineffective when utilizing other approaches.

1. Ahn S.Y., Chang Y.S., Park W.S.: Mesenchymal stem cells transplantation for neuroprotection in preterm infants with severe intraventricular hemorrhage. Korean J Pediatr 57(6):251-6,2014. doi:

2. Bajek A., Olkowska J., Drewa T.: Mesenchymal stem cells as a therapeutic tool in tissue and organ regeneration. Postepy Hig Med Dosw 24;65:124-32,2011.

3. Ball L.M., et al.: Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol. 163(4):501-9. 2013. doi:

4. Barry F.P., et al.: The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105). Biochem Biophys Res Commun 265(1):134-9, 1999.

5. Boruczkowski D., Korytowska-Niklas A., Bręborowicz A.: Zastosowanie komórek macierzystych w terapii chorób układu oddechowego - możliwości i nadzieje. Alergia Astma Immunologia 18 (3): 170-174, 2013.

6. Boruczkowski D., et al.: Krew pępowinowa. Część trzecia - przyszłość [Cord blood. Part three - the future]. Nowa Pediatria 3:61-65, 2011.

7. Caplan A.I.: Mesenchymal stem cells. J Orthop Res 9(5):641-50, 1991.

8. Chang Y.S., et al.: Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. J Pediatr 164(5):966- 972, 2014. e6. doi:

9. Chicha L., Smith T., Guzman R.: Stem cells for brain repair in neonatal hypoxia-ischemia. Childs Nerv Syst , 30(1):37-46,2014. doi:

10. Ciccocioppo R., et al.: Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut 60(6):788-98, 2011. doi:

11. Dalal J, Gandy K, Domen J.: Role of mesenchymal stem cell therapy in Crohn’s disease. Pediatr Res 71(4 Pt 2):445-51, 2012. doi:

12. Dominici M., et al.: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315-7,2006.

13. Fang B, et al.: Cotransplantation of haploidentical mesenchymal stem cells to enhance engraftment of hematopoietic stem cells and to reduce the risk of graft failure in two children with severe aplastic anemia. Pediatr Transplant 13(4):499-502,2009. doi:

14. Farivar S., et al.: Neural differentiation of human umbilical cord mesenchymal stem cells by cerebrospinal fluid. Iran J Child Neurol 9(1):87-93, 2015.

15. Friedenstein A.J., et al.: Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 17(4):331-40, 1974.

16. Gentili C., Torre M., Cancedda R.: Tissue engineering approaches in skeletal pediatric disorders. Eur J Pediatr Surg 24(3):263-9, 2014. doi:

17. Gortner L., et al.: Regenerative therapies in neonatology: clinical perspectives. Klin Padiatr 224(4):233-40, 2012.

18. Götherström C., et al.: Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two-center experience. Stem Cells Transl Med 3(2):255-64, 2014. doi:

19. Heijnen C.J., Witt O., Wulffraat N., Kulozik A.E.: Stem cells in pediatrics: state of the art and future perspectives. Pediatr Res 71(4 Pt 2):407-9,2012. doi:

20. Hibi H., Yamada Y., Ueda M., Endo Y.: Alveolar cleft osteoplasty using tissue-engineered osteogenic material. Int J Oral Maxillofac Surg 35(6):551-5,2006.

21. Hu J., et al.: Long term effects of the implantation of Wharton’s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocr J 60(3):347-57, 2013.

22. Introna M., et al.: Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transplant. 20(3):375-81, 2014. doi:

23. Jin J.L., et al.: Safety and efficacy of umbilical cord mesenchymal stem cell therapy in hereditary spinocerebellar ataxia. Curr Neurovasc Res 10(1):11-20,2013.

24. Jozwiak S., et al.: Intracerebroventricular Transplantation of Cord Blood-Derived Neural Progenitors in a Child With Severe Global Brain Ischemic Injury. Cell Medicine 1,2:71-80,2010.

25. Jung J.W., et al.: Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy. Yonsei Med J 54(5):1293-6, 2013. doi:

26. Krenska A., et al.: The use of mesenchymal stem cells in therapy of steroid-resistance chronic refractory graft-versus-host disease after hematopoietic stem cell transplantation. Medical and Biological Sciences 28, 3, 57-61, 2014.

27. Kurtzberg J., et al.: Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biol Blood Marrow Transplant 20(2):229-35, 2014. doi:

28. Lacis A., Erglis A.: Intramyocardial administration of autologous bone marrow mononuclear cells in a critically ill child with dilated cardiomyopathy. Cardiol Young 21(1):110-2, 2011. doi:

29. Le Blanc K., et al.: Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 10;371:1579-86, 2008. doi:

30. Liang J., et al.: Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis 69(8):1423-9, 2010. doi:

31. Lv Y.T., et al.: Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. J Transl Med 27;11:196, 2013. doi:

32. Mei S.H., et al.: Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 15;182(8):1047-57, 2010. doi:

33. Norambuena G.A., Khoury M., Jorgensen C.: Mesenchymal stem cells in osteoarticular pediatric diseases: an update. Pediatr Res 71 (4Pt2):452-8, 2012. doi:

34. Pal R., et al.: Ex vivo-expanded autologous bone marrow-derived mesenchymal stromal cells in human spinal cord injury/paraplegia: a pilot clinical study. Cytotherapy 11(7):897-911, 2009. doi:

35. Pesmatzoglou M., Dimit r iou H., St iakaki E .: Could mesenchymal st romal cel ls have a role in chi ldhood autoimmune diseases? Immunol Invest 42(7):639-56. 2013. doi:

36. Prasad V.K., et al.: Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 17(4):534-41, 2011. doi:

37. Selem S.M., Kaushal S., Hare J.M.: Stem cell therapy for pediatric dilated cardiomyopathy. Curr Cardiol Rep 15(6):369, 2013. doi:

38. Sun L., et al.: Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 62(8):2467-75, 2010. doi:

39. Sun Y., Zhang F.S., Zhang Z.Y.: Immunoregulatory effect of bone marrow mesenchymal stem cells on regulatory T cells in patients with systemic lupus erythematosis. Zhonghua Nei Ke Za Zhi 46(12):1018-21, 2007.

40. Tyndall A.: Application of autologous stem cell transplantation in various adult and pediatric rheumatic diseases. Pediatr Res 71(4 Pt 2):433-8, 2012. doi:

41. van Velthoven C.T., Gonzalez F., Vexler Z.S., Ferriero D.M.: Stem cells for neonatal stroke- the future is here. Front Cell Neurosci 25;8:207, 2014. doi:

42. Vassena R., et al.: ESHRE special interest group Stem Cells. Stem cells in reproductive medicine: ready for the patient? Hum Reprod 30(9):2014-21, 2015. doi:

43. Wakitani S., et al.: Autologous bone marrow stromal cell transplantation for repair of full-thickness articular cartilage defects in human patellae: two case reports. Cell Transplant 13(5):595-600, 2004.

44. Wernicke C.M., et al.: Mesenchymal stromal cells for treatment of steroid-refractory GvHD: a review of the literature and two pediatric cases. Int Arch Med 15;4(1):27, 2011.doi:

45. Wong R.S.Y., Mesenchymal stem cells: Angels or demons? J of Biomed Biotechnol 459510, 2011.


47. Zheng J.C., Tong Z.: Exciting progresses in stem cell and neural stem cell research. Curr Mol Med 13(9):1409-11, 2013.

Current Issues in Pharmacy and Medical Sciences

Formerly Annales UMCS Sectio DDD Pharmacia

Journal Information

CiteScore 2018: 0.32

SCImago Journal Rank (SJR) 2018: 0.154
Source Normalized Impact per Paper (SNIP) 2018: 0.285


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 308 184 5
PDF Downloads 141 93 3